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Population-level cancer incidence rates are one measure to estimate the cancer burden. 
The goal is to provide information on trends to measure progress against cancer at the 
population level and identify emerging patterns signifying increased risk for additional 
research and intervention. Endometrial cancer is the most common of the gynecologic 
malignancies but capturing the incidence of disease among women at risk (i.e., women 
with a uterus) is challenging and not routinely published. Decreasing rates of hysterec-
tomy increase the number of women at risk for disease, which should be reflected in 
the denominator of the incidence rate calculation. Furthermore, hysterectomy rates vary 
within the United States by multiple factors including geographic location, race, and 
ethnicity. Changing rates of hysterectomy are important to consider when looking at 
endometrial cancer trends. By correcting for hysterectomy when calculating incidence 
rates of cancers of the uterine corpus, many of the disparities that have been assumed 
for this disease are diminished.
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inTRODUCTiOn
Hysterectomy is one of the most frequently performed surgical procedures among women of 
reproductive age in the United States, second only to cesarean delivery. Approximately 600,000 
hysterectomies are performed annually in the United States (1). An estimated 20 million US women 
have had a hysterectomy; more than one-third of all women have had a hysterectomy by age 60 
(1–3). Multiple factors impact hysterectomy rates, including geography and race. Since the 1980s, 
alternative treatments for menorrhagia, fibroids, and endometriosis have been developed and 
increased in popularity, leading to decreasing rates of hysterectomy. An inadvertent consequence 
of these trends toward conservative surgical management of the female genital tract may be an 
apparent increase in the incidence of gynecologic malignancies specifically cancers of the uterine 
corpus. Women who have had a hysterectomy are no longer at risk of endometrial or cervical 
cancer. Failure to remove these women from the population at-risk leads to an underestimate 
of endometrial cancer incidence rates. Although a higher number of women at risk may lead to 
additional cases as hysterectomy rates decrease, the incidence rate should not be affected since it is 
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meant to measure the number of new cases per 100,000 women 
in the population at risk for disease. Gynecologic cancer trends 
over time also are impacted by changes in the proportion of 
women with their uterus retained, as they reach ages when these 
malignancies occur. This paper describes the potential impact 
of recent changes rates of hysterectomy over time by race and 
period cohorts.
HYSTeReCTOMY TRenDS
The majority of hysterectomies are performed for benign indica-
tions, with fewer than 15% performed for a malignant preopera-
tive diagnosis (2, 4, 5). The most common primary indications 
are abnormal uterine bleeding, uterine leiomyomata, and endo-
metriosis (6). Alternatives to hysterectomy including hormonal 
management, operative hysteroscopy, endometrial ablation, 
uterine artery embolization, and use of the levo-norgestrel 
intrauterine device (IUD) as primary management of these con-
ditions have become available and have been demonstrated to be 
safe (7, 8). The availability of these options has raised questions 
about potential overuse of hysterectomy. The decreased morbid-
ity associated with uterus-sparing therapies has contributed to 
their popularity. In addition, the rising age of first pregnancy 
and improvements in assisted reproduction have made fertility 
concerns important to women later into life, and contributed to 
the popularity of uterine preservation. Lastly, although adnexal 
surgery (e.g., for ovarian cysts) historically triggered a hyster-
ectomy in addition to oophorectomy, the automatic inclusion 
of hysterectomy in this setting has fallen out of favor. A more 
conservative approach to the management of ovarian cysts has 
become more standard, as growing evidence suggests that many 
ovarian cysts are low risk for malignancy and can safely be 
monitored by ultrasonography (9, 10). These factors combined 
have led to recently declining hysterectomy rates (2, 3, 5, 11–13). 
This decline has been most dramatic among postmenopausal 
women; the rate of decline has been mostly among white women 
compared to other racial and ethnic groups (2, 5).
Hysterectomy by the lesser invasive laparoscopic approaches 
has become more common than either vaginal or abdominal 
hysterectomy; minimally invasive hysterectomy has also been 
shown to be an increasingly safer procedure and can be done 
as an outpatient procedure (3, 4). Population level evidence 
suggests an increase in all-cause mortality with surgical 
menopause, resulting in many more women undergoing hys-
terectomy without oophorectomy (2, 5). Variations in totality 
of hysterectomy vary by race with black women less likely to 
have their cervix or ovaries removed with their uterus (14, 15). 
This trend may be leaving more women undergoing partial pro-
cedures in an effort to decrease morbidity and cost, despite the 
benefits associated with the performance of minimally invasive 
hysterectomy. Although these changes to patterns of surgical 
care may affect incidence rates of all gynecologic malignancies, 
we focus here on the consequences to rates of cancers of the 
uterine corpus.
FACTORS ASSOCiATeD wiTH 
HYSTeReCTOMY
The prevalence of hysterectomy within a population varies by 
community and patient-level factors. Community-level factors 
include facility type. It has been observed that the procedure more 
frequently is performed in community hospitals than academic 
centers (3). Additional factors, such as physician gender, age, level 
of education, and local physician density, play a role in whether 
hysterectomy is recommended and performed (16, 17).
Furthermore, hysterectomy prevalence varies greatly by 
patient race and ethnicity. Several studies have estimated hys-
terectomy prevalence from population-based survey data and 
have shown that hysterectomy rates are markedly higher among 
black women compared to white and Hispanic women even in 
recent years (12, 18–20). Specifically, age-adjusted hysterectomy 
prevalence from 2004 to 2008 in women age 20 and older was 23% 
among black women compared to 20 and 17% among white and 
Hispanic women, respectively (18). Hysterectomy prevalence is 
lowest among Asian and Pacific Islanders (API) (6, 12) and Alaska 
Native/American Indian women have a prevalence intermediate 
between black and white women (14, 21). Moreover, hysterec-
tomy prevalence has been declining in the Northeast region of 
the United States (2). Jamison et al. also showed a decline among 
white women from the early 1990s to 2008. However, hysterec-
tomy was relatively stable among black women during this time 
period (Figure 1) (12).
There also are racial and ethnic differences in the prevalence of 
common benign gynecologic conditions and the use of surgical 
treatments. Specifically, black women reportedly have higher rates 
of fibroids, which are the most common benign indication for hys-
terectomy. Higher rates of hysterectomy are commonly attributed 
to the greater prevalence of uterine fibroids among black women, 
rather than a disparity in care. Black women had 3.3 times the odds 
of receiving a diagnosis of fibroid tumors by pelvic examination, 
ultrasound scans, or hysterectomy compared to white women in 
the Nurses’ Health Study II (22). The higher frequency of hyster-
ectomy in the South compared to other geographic regions of the 
United States is another potential reason that hysterectomy may 
be more common among black women (3, 18).
Several large studies have reported higher rates of hysterec-
tomy among black women even when adjusted for common clini-
cal and demographic factors that are associated with undergoing 
hysterectomy (15, 23, 24). An analysis of data from the CARDIA 
study found black women to have nearly four times the odds of 
undergoing hysterectomy, compared with white women, after 
controlling for BMI, polycystic ovarian syndrome, tubal ligation, 
depressive symptoms, age at menarche, education, access to 
medical care, geographic site, and a diagnosis of fibroid tumors 
(OR, 3.7; 95% CI, 2.4–5.6) (23). Similarly, the Study of Women 
across the Nation (SWAN) included self-reported hysterectomy 
for benign indications. Black women were 1.7 times more likely to 
undergo hysterectomy (OR, 1.7; 95% CI, 1.5–1.9) after controlling 
for education, geographic site, age, marital status, fibroid tumors, 
parity, smoking, and social support (24). Social determinants 
FiGURe 1 | e-adjusted hysterectomy rates by race among women age 
50 and older in the SeeR-13 states 1992–2008. Footnote: data from the 
Behavioral Risk Factor Surveillance System, Centers for Disease Control and 
Prevention. States included are: California, Connecticut, Iowa, Georgia, 
Hawaii, Michigan, New Mexico, Utah, and Washington.
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of health including differences in patient preferences, physician 
influence, quality of available care, and access to hysterectomy 
alternatives also likely influence hysterectomy rates between 
racial and ethnic groups (15).
iMPACT OF HYSTeReCTOMY On 
enDOMeTRiAL CAnCeR RATeS  
AnD TRenDS
Over 60,000 women in the US are expected to be diagnosed 
with cancers of the uterine corpus in 2001, making it the most 
common of the gynecologic malignancies (25). Incidence rates 
for endometrial cancer have continued to climb over the last 
decade and are projected to continue to increase (26–28). 
Incidence of uterine cancer has been shown to vary by race and 
ethnicity, with the highest rates among white women, and the 
lowest rates among Asian women (29). Incidence rates from the 
population-based Surveillance Epidemiology and End Results 
(SEER) program, from 2008 to 2012, were highest among white 
women (25.8 cases per 100,000 women) followed by black 
(24.0 cases per 100,000), Hispanic (20.7 cases per 100,000), 
and Asian Pacific Islander women (19.9 cases per 100,000) 
(30). Since women who have undergone a hysterectomy are no 
longer at risk for endometrial cancer, failure to remove them 
from the  denominator of the population at risk results in dif-
ferential underestimation of rates of disease among race and 
ethnic population (14, 18, 19, 31). Correcting incidence rates 
by removing these women from the population at risk has 
been shown to markedly change the rates in the population 
(18, 19, 21, 31–36). Uncorrected cancer incidence trends over 
time do not accurately represent the underlying risk of disease, 
as hysterectomy rates and indications have changed over time 
and vary by racial groups and geographic region.
The difference in uterine cancer rates between white and black 
women is diminished after correction for hysterectomy, while 
the differences between white and Hispanic women are accentu-
ated (12, 18, 19, 31). Specifically, Siegel and colleagues recently 
reported that hysterectomy-corrected rates among white women 
in the US were 61% higher, 78% higher for black women, and 
47% higher for Hispanic women. Correcting for hysterectomy 
changed the relative risk of endometrial cancer for black women 
in the US from 0.87 (95% CI 0.86–0.88) to 0.97 (95% CI 0.94–1.0) 
making the racial disparity in endometrial cancer incidence 
between black and white women no longer statistically sig-
nificant. This underestimation varied greatly by state, which have 
different rates of hysterectomy. After adjusting for hysterectomy, 
black women still had a higher risk of uterine corpus cancers in 
Washington, DC, Florida, North and South Carolina, and a lower 
risk in Pennsylvania, New Jersey, and New York. The rest of the 
states with significant disparities lost their significance when cor-
rected for hysterectomy (Alabama, California, Illinois, Indiana, 
Kentucky, Massachusetts, Michigan, Mississippi, Missouri, Ohio, 
Tennessee, and Virginia) (18).
Trends of uterine cancer over time also are distorted since 
hysterectomy rates are changing over time differentially with 
respect to race and geography (12). The hysterectomy-corrected 
incidence of uterine corpus cancers among black women is 
increasing significantly at 3.1% per year nearly double the 
1.8% annual increase based on uncorrected incidence rates 
(Figure  2). Correction of the incidence trends also reveals a 
crossover where the incidence for black women is higher than 
for whites around the mid 2000s bringing the incidence rates of 
endometrial cancer for black women higher than that of whites 
(12). The incidence rates for white women have been decreasing 
since 1992, and the effect is attenuated without correction for 
hysterectomy. Specifically, incidence rates decrease 0.8% annu-
ally after hysterectomy correction compared to an annual decline 
of 0.5% uncorrected.
A recent analysis from the Epidemiology of Endometrial 
Cancer Consortium pooled data from seven cohort and four 
case-control studies and analyzed the effects of known risks for 
endometrial cancer in white and black women. Obesity, diabetes, 
smoking, and oral contraceptive use had similar effects on the 
risk of disease across groups, indicating that the prevalence dif-
ferences of these risk factors may partially contribute to racial 
disparities in rates of uterine cancers (37). Adjusting cancer inci-
dence rates corrected for hysterectomy prevalence, particularly 
when reporting for racial disparities in cancer rates is necessary, 
given the multiple factors affecting hysterectomy rates includ-
ing geographic region, race, and ethnicity.
FiGURe 2 | Age-adjusted endometrial cancer incidence rates by race among women age 50 and older in SeeR-13, 1992–2008. (A) All types; (B) Type I 
cancers; (C) Type II cancers.
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RiSK FACTORS AnD TYPeS OF UTeRine 
CAnCeR OveR TiMe
The vast majority of cancers of the uterine corpus arise from 
the endometrium. Obesity and its associated high circulating 
estrogen concentrations, is the primary risk factor for the devel-
opment of endometrial cancer. However, the aging population, 
the widespread decrease in the use of hormone replacement 
therapy, particularly progesterone-based agents, population level 
delays in childbearing, and the increasing prevalence of diabetes 
all likely factor in the changing incidence over time (26, 27, 
38). Endometrial cancer tends to be diagnosed at an early stage 
with over 80% of the over 55,000 patients with uterine cancer 
diagnosed with local disease (39). Although the vast majority 
of women are cured following a diagnosis and intervention of 
early stage uterine cancer, in 2011, the incidence rate was 27.5 
per 100,000 women and the 5-year relative survival rate was 83% 
for women diagnosed in 2005 to 2011 (39). This is compared to 
the mid 1970s when the incidence rate was higher at 35.5 per 
100,000 women, and the 5-year relative survival was higher at 
87% (40). Despite improvements in therapeutic options, 5-year 
survival appears to have declined (41).
This malignancy has been historically divided into a Type I and 
Type II based upon the typical biologic behavior of the disease. 
Type I disease is the more common, low grade form of this malig-
nancy and tends to be diagnosed in younger women and is driven 
by excess estrogen states such as obesity. The Type I endometrial 
cancers are usually caught at an early stage where survival is likely. 
Type II endometrial cancer, including high-grade endometrioid, 
serous, and clear-cell carcinoma, and carcinosarcomas, however, 
is typically estrogen independent, occurs in older women and 
is more likely to be metastatic at diagnosis (42). Increasing 
proportions of Type II endometrial cancer are being seen in our 
population and may be due to the aging population where more 
women age with their uterus intact. This increases the proportion 
of higher risk and morbid uterine cancers.
Having undergone a hysterectomy for benign indications 
eliminates the risk for de novo development of endometrial can-
cer. But hysterectomy alternatives are likely altering endometrial 
cancer risk as well. Consideration can be given for the possibility 
that women who had a hysterectomy are more likely to have strong 
risk factors for Type I endometrial cancer (such as those with 
PCOS, endometriosis, or other hormonal imbalances leading 
to symptomatic benign gynecologic conditions). Hysterectomy 
may then selectively remove women at highest risk for low grade 
malignancies with low mortality rates. Additionally, as women are 
less likely to undergo hysterectomy and accept alternate therapy 
for menorrhagia, fibroids, or dysmenorrhea, they may be exposed 
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to hormonal agents such as the levo-norgestrol IUD and other 
long acting contraceptive agents. These hormonal interventions 
are protective against Type I endometrial cancer.
After correcting for hysterectomy prevalence, the difference in 
incidence rates for Type I cancer diminishes between white and 
black women over time, largely due to the increasing rates of Type 
I cancers among black women and the decrease in Type I cancers 
among white women. Much of this difference may be attribut-
able to increased risk factors for endometrial cancer among black 
women compared to non-black women such as obesity, diabetes, 
and decreased use of oral contraception (19, 37).
Black women are diagnosed proportionally more frequently 
with aggressive Type II disease, compared with other racial/
ethnic groups (41, 43–49). Uncorrected, incident invasive uterine 
cancer cases between 1999 and 2006 collected from the Centers 
for Disease Control and Prevention’s National Program of Cancer 
Registries or the National Cancer Institute’s SEER Program 
revealed that only 6.8% of all endometrial cancer patients are 
black but they represent 17.4% of type II endometrial cancers (48). 
Rates of Type II cancers appear to be increasing over time entirely 
due to an increase in incidence among black women (Figure 2) 
(12). While hormonal hysterectomy alternatives are known be 
protective against Type I cancers, their role in the development 
of Type II endometrial cancers is less clear.
The racial disparity in uterine cancer mortality is pronounced. 
Despite a 30% lower incidence of disease among black women, 
the mortality rate is 80% higher when compared to whites (49). 
Histologic differences have historically been used to explain dif-
ferences in mortality rates between white and black women, and 
certainly, a larger proportion of Type II malignancies seen in black 
women contributes to this difference. As with other disparities 
however, the role of access to care cannot be overlooked. A recent, 
large analysis of women with Type II endometrial cancer using 
SEER-Medicare data suggested that controlling for treatment and 
socioeconomic differences, and medical comorbidities eliminated 
the difference in the disease-specific mortality between black and 
white women (50). Disparities related to access to care (specifi-
cally hysterectomy alternatives) may amplify the effects of inter-
ventions that change risks for the development of gynecologic 
malignancies. As our understanding of the molecular and genetic 
factors that correlate to prognosis expands through projects such 
as the TCGA, ensuring adequate minority participation to clini-
cal trials must be a priority. More research is needed, but many 
of the disparities in endometrial cancer between black and white 
women may be explained by hysterectomy rates, access to hor-
monal hysterectomy alternatives, and differences in risk factors 
such as obesity.
COnCLUSiOn
An unintended consequence of non-surgical management of 
common gynecologic conditions appears to be rising incidence 
and mortality of cancer of the uterine corpus. Incidence and 
prevalence rates of cancer are useful indicators for assessing the 
health of a population. Accurate rates are needed in order to 
determine population level needs and to understand and health 
disparities among subgroups. As risk reducing surgical removal 
of other organs (e.g., breast, fallopian tubes, and ovaries) becomes 
increasingly common, this issue may extend to other cancer 
disease sites. In endometrial cancer incidence rates uncorrected 
for hysterectomy have been used to describe wide variations in 
geographic and racial and ethnic differences in risks of the devel-
opment of disease. But hysterectomy-corrected rates may help to 
explain some of the variations as related to patterns of care, access 
to care, and other non-biologic factors and provide information 
for appropriately targeting populations to reduce other risk fac-
tors such as obesity.
AUTHOR COnTRiBUTiOnS
Conception: ST and A-MN. Writing: ST, A-MN, and LM. 
Reviewing: ST, A-MN, and LM.
FUnDinG
This work was supported by the National Cancer Institute’s 
Surveillance Research Program within the Division of Cancer 
Control and Population Sciences and Office of the Director 
within the Division of Cancer Prevention.
ReFeRenCeS
1. ACOG. Choosing the route of hysterectomy for benign disease. ACOG 
Committee Opinion No. 444. Obstet Gynecol (2009) 114:1156–8. doi:10.1097/
AOG.0b013e3181c33c72 
2. Whiteman MK, Hillis SD, Jamieson DJ, Morrow B, Podgornik MN, Brett KM, 
et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am 
J Obstet Gynecol (2008) 198(1):.e1–7. doi:10.1016/j.ajog.2007.05.039 
3. Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu Y-S, et  al. 
Nationwide trends in the performance of inpatient hysterectomy in the 
United States. Obstet Gynecol (2013) 122(2 Pt 1):233–41. doi:10.1097/ 
AOG.0b013e318299a6cf 
4. Cohen SL, Vitonis AF, Einarsson JI. Updated hysterectomy surveillance 
and factors associated with minimally invasive hysterectomy. JSLS (2014) 
18(3):e2014.00096. doi:10.4293/JSLS.2014.00096 
5. Merrill RM. Hysterectomy surveillance in the United States, 1997 through 
2005. Med Sci Monit (2008) 14(1):24–31. 
6. Merrill RM, Layman AB, Oderda G, Asche C. Risk estimates of hysterectomy 
and selected conditions commonly treated with hysterectomy. Ann Epidemiol 
(2008) 18(3):253–60. doi:10.1016/j.annepidem.2007.10.011 
7. ACOG. ACOG practice bulletin: alternatives to hysterectomy in the man-
agement of leiomyomas. Obstet Gynecol (2008) 112(2):387–99. doi:10.1097/
AOG.0b013e318183fbab 
8. Sutton C. Past, present, and future of hysterectomy. J Minim Invasive Gynecol 
(2010) 17(4):421–35. doi:10.1016/j.jmig.2010.03.005 
9. Suh-Burgmann E, Hung Y-Y, Kinney W. Outcomes from ultrasound follow-up 
of small complex adnexal masses in women over 50. Am J Obstet Gynecol 
(2014) 211(6):.e1–7. doi:10.1016/j.ajog.2014.07.044 
10. Pavlik EJ, Ueland FR, Miller RW, Ubellacker JM, DeSimone CP, Elder J, et al. 
Frequency and disposition of ovarian abnormalities followed with serial 
transvaginal ultrasonography. Obstet Gynecol (2013) 122(2 Pt 1):210–7. 
doi:10.1097/AOG.0b013e318298def5 
11. ACOG. Hysterectomy. In: Gynecologists ACOG, editor. Women’s Health Stats 
& Facts. Washington, DC: ACOG (2011). p. 19–20.
6Temkin et al. Hysterectomy Rates and Endometrial Cancer
Frontiers in Oncology | www.frontiersin.org April 2016 | Volume 6 | Article 89
12. Jamison PM, Noone A-M, Ries LAG, Lee NC, Edwards BK. Trends in 
endometrial cancer incidence by race and histology with a correction for the 
prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers 
Prev (2013) 22(2):233–41. doi:10.1158/1055-9965.EPI-12-0996 
13. Jacobson GF, Shaber RE, Armstrong MA, Hung Y-Y. Hysterectomy rates for 
benign indications. Obstet Gynecol (2006) 107(6):1278–83. doi:10.1097/01.
AOG.0000210640.86628.ff 
14. Merrill RM. Impact of hysterectomy and bilateral oophorectomy on 
 race-specific rates of corpus, cervical, and ovarian cancers in the United States. 
Ann Epidemiol (2006) 16(12):880–7. doi:10.1016/j.annepidem.2006.06.001 
15. Jacoby VL, Fujimoto VY, Giudice LC, Kuppermann M, Washington AE. 
Racial and ethnic disparities in benign gynecologic conditions and associ-
ated surgeries. Am J Obstet Gynecol (2010) 202(6):514–21. doi:10.1016/j.
ajog.2010.02.039 
16. Bickell NA, Earp JA, Garrett JM, Evans AT. Gynecologists’ sex, clinical 
beliefs, and hysterectomy rates. Am J Public Health (1994) 84(10):1649–52. 
doi:10.2105/AJPH.84.10.1649 
17. Geller SE, Burns LR, Brailer DJ. The impact of nonclinical factors on practice 
variations: the case of hysterectomies. Health Serv Res (1996) 30(6):729–50. 
18. Siegel RL, Devesa SS, Cokkinides V, Ma J, Jemal A. State-level uterine corpus 
cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. 
Cancer Epidemiol Biomarkers Prev (2013) 22(1):25–31. doi:10.1158/1055-
9965.EPI-12-0991 
19. Sherman ME, Carreon JD, Lacey JV, Devesa SS. Impact of hysterectomy on 
endometrial carcinoma rates in the United States. J Natl Cancer Inst (2005) 
97(22):1700–2. doi:10.1093/jnci/dji378 
20. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence 
of cervical cancer after correction for hysterectomy prevalence in the United 
States from 2000 to 2009. Cancer (2014) 120(13):2032–8. doi:10.1002/
cncr.28548 
21. Wong C, Jim M, King J, Tom-Orme L, Henderson J, Saraiya M, et al. Impact of 
hysterectomy and bilateral oophorectomy prevalence on rates of cervical, uter-
ine, and ovarian cancer among American Indian and Alaska Native women, 
1999–2004. Cancer Causes Control (2011) 22(12):1681–9. doi:10.1007/
s10552-011-9844-2 
22. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, 
Colditz GA, et  al. Variation in the incidence of uterine leiomyoma among 
premenopausal women by age and race. Obstet Gynecol (1997) 90(6):967–73. 
doi:10.1016/S0029-7844(97)00534-6 
23. Bower JK, Schreiner PJ, Sternfeld B, Lewis CE. Black–White differences in 
hysterectomy prevalence: the CARDIA Study. Am J Public Health (2009) 
99(2):300–7. doi:10.2105/AJPH.2008.133702 
24. Powell LH, Meyer P, Weiss G, Matthews KA, Santoro N, Randolph JF Jr, et al. 
Ethnic differences in past hysterectomy for benign conditions. Womens Health 
Issues (2005) 15(4):179–86. doi:10.1016/j.whi.2005.05.002 
25. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin (2016) 
66(1):7–30. doi:10.3322/caac.21332 
26. Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B. Recent 
changes in endometrial cancer trends among menopausal-age US women. 
Cancer Epidemiol (2013) 37(4):374–7. doi:10.1016/j.canep.2013.03.008 
27. Sheikh MA, Althouse AD, Freese KE, Soisson S, Edwards RP, Welburn S, 
et al. USA Endometrial Cancer Projections to 2030: should we be concerned? 
Future Oncol (2014) 10(16):2561–8. doi:10.2217/fon.14.192 
28. Duncan ME, Seagroatt V, Goldacre MJ. Cancer of the body of the uterus: 
trends in mortality and incidence in England, 1985–2008. BJOG (2012) 
119(3):333–9. doi:10.1111/j.1471-0528.2011.03201.x 
29. Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden 
of endometrial cancer: a major racial disparity affecting black women. Cancer 
Epidemiol Biomarkers Prev (2015) 24(9):1407–15. doi:10.1158/1055-9965.
EPI-15-0316 
30. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. 
SEER Cancer Statistics Review (CSR) 1975-2012. Bethesda, MD: National 
Cancer Institute (2015).
31. Stang A, Hawk H, Knowlton R, Gershman ST, Kuss O. Hysterectomy-corrected 
incidence rates of cervical and uterine cancers in Massachusetts, 1995 to 2010. 
Ann Epidemiol (2014) 24(11):849–54. doi:10.1016/j.annepidem.2014.07.018 
32. Redburn JC, Murphy MFG. Hysterectomy prevalence and adjusted cervical 
and uterine cancer rates in England and Wales. BJOG (2001) 108(4):388–95. 
doi:10.1111/j.1471-0528.2001.00098.x 
33. Luoto R, Raitanen J, Pukkala E, Anttila A. Effect of hysterectomy on incidence 
trends of endometrial and cervical cancer in Finland 1953–2010. Br J Cancer 
(2004) 90(9):1756–9. doi:10.1038/sj.bjc.6601763 
34. Stang A. Impact of hysterectomy on the age-specific incidence of cervical and 
uterine cancer in Germany and other countries. Eur J Public Health (2012) 
23(5):879–83. doi:10.1093/eurpub/cks080 
35. Stang A, Merrill R, Kuss O. Prevalence-corrected hysterectomy rates by 
age and indication in Germany 2005–2006. Arch Gynecol Obstet (2012) 
286(5):1193–200. doi:10.1007/s00404-012-2415-2 
36. Hammer A, Rositch AF, Kahlert J, Gravitt PE, Blaakaer J, Søgaard M. Global 
epidemiology of hysterectomy: possible impact on gynecological cancer rates. 
Am J Obstet Gynecol (2015) 213(1):23–9. doi:10.1016/j.ajog.2015.02.019 
37. Cote M, Alhajj T, Ruterbusch J, Bernstein L, Brinton L, Blot W, et  al. Risk 
factors for endometrial cancer in black and white women: a pooled analysis 
from the epidemiology of endometrial cancer consortium (E2C2). Cancer 
Causes Control (2015) 26(2):287–96. doi:10.1007/s10552-014-0510-3 
38. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body 
mass index, hormone replacement therapy, and endometrial cancer risk: a 
meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 19(12):3119–30. 
doi:10.1158/1055-9965.EPI-10-0832 
39. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin (2015) 
65(1):5–29. doi:10.3322/caac.21254 
40. Silverberg E, Lubera J. Cancer statistics, 1987. CA Cancer J Clin (1987) 
37(1):2–19. doi:10.3322/canjclin.37.1.2 
41. Wright JD, Fiorelli J, Schiff PB, Burke WM, Kansler AL, Cohen CJ, et al. Racial 
disparities for uterine corpus tumors: changes in clinical characteristics and 
treatment over time. Cancer (2009) 115(6):1276–85. doi:10.1002/cncr.24160 
42. Sorosky JI. Endometrial cancer. Obstet Gynecol (2012) 120(2 Pt 1):383–97. 
doi:10.1097/AOG.0b013e3182605bf1 
43. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treat-
ment, and survival among African Americans in the United States. Gynecol 
Oncol (2013) 130(3):652–9. doi:10.1016/j.ygyno.2013.05.020 
44. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, 
and mortality for malignant tumors of the uterine corpus. Cancer (2003) 
98(1):176–86. doi:10.1002/cncr.11484 
45. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson 
BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic 
cohort study. Am J Epidemiol (2007) 165(3):262–70. doi:10.1093/aje/kwk010 
46. Hicks ML, Phillips JL, Parham G, Andrews N, Jones WB, Shingleton HM, 
et  al. The National Cancer Data Base report on endometrial carcinoma in 
African-American women. Cancer (1998) 83(12):2629–37. doi:10.1002/
(SICI)1097-0142(19981215)83:12<2629::AID-CNCR30>3.0.CO;2-2 
47. Oliver KE, Enewold LR, Zhu K, Conrads TP, Rose GS, Maxwell GL, et  al. 
Racial disparities in histopathologic characteristics of uterine cancer are 
present in older, not younger blacks in an equal-access environment. Gynecol 
Oncol (2011) 123(1):76–81. doi:10.1016/j.ygyno.2011.06.027 
48. Duong LM, Wilson RJ, Ajani UA, Singh SD, Eheman CR. Trends in endome-
trial cancer incidence rates in the United States, 1999-2006. J Womens Health 
(2011) 20(8):1157–63. doi:10.1089/jwh.2010.2529 
49. Farley J, Risinger JI, Rose GS, Maxwell GL. Racial disparities in Blacks with 
gynecologic cancers. Cancer (2007) 110(2):234–43. doi:10.1002/cncr.22797 
50. Rauh-Hain JA, Buskwofie A, Clemmer J, Boruta DM, Schorge JO, Del Carmen 
MG. Racial disparities in treatment of high-grade endometrial cancer in the 
medicare population. Obstet Gynecol (2015) 125(4):843–51. doi:10.1097/
AOG.0000000000000605 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The reviewer BD and handling Editor declared their shared affiliation, and the 
handling Editor states that the process nevertheless met the standards of a fair and 
objective review.
Copyright © 2016 Temkin, Minasian and Noone. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
